Overview
A Study of Patients With Primary Open Angle Glaucoma or Ocular Hypertension Switched to Lumigan® UD Monotherapy for Medical Reasons
Status:
Completed
Completed
Trial end date:
2014-03-01
2014-03-01
Target enrollment:
0
0
Participant gender:
All
All
Summary
The study will evaluate patients diagnosed with primary open angle glaucoma or ocular hypertension who are switched to Lumigan® UD monotherapy for medical reasons in accordance with physician standard clinical practice. All treatment decisions lie with the physician.Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
AllerganTreatments:
Bimatoprost
Ophthalmic Solutions
Pharmaceutical Solutions
Criteria
Inclusion Criteria:- Diagnosed with primary open-angle glaucoma or ocular hypertension
- Previously prescribed intraocular pressure (IOP)-lowering medication with insufficient
IOP control and is now being switched to Lumigan® UD for medical reasons
Exclusion Criteria:
- None